teams, 5, 6 prison inmates, 7 and child care attendees, 8 usually involved skin dis ease, MRSA also can cause severe, some times fatal invasive disease. [9] [10] [11] [12] [13] Studies of the emergence of commu nity-associated MRSA disease over the past decade determined that isolates causing community-associated and health care-associated MRSA infec tions were distinct. 10 Isolates from the community were susceptible to most non-�-lactam antimicrobial agents, 10 carried staphylococcal cassette chro mosome type IV, 14 and frequently en coded the dermonecrotic cytotoxin known as Panton-Valentine leukoci din. 15 The strain most often isolated in community outbreaks was pulsedfield type USA300. 16 Other strains of community origin include USA400, USA1000, and USA1100. 17 In con trast, strains most frequently associ ated with MRSA infections in health care settings were USA100, USA200, and less often, USA500 18 ; these tradi tionally have been multidrug resistant and have carried staphylococ cal cassette chromosome type II. 10 In hospitalized patients, MRSA has been a problem since the 1960s 19 ; ap proximately 20% of bloodstream infec tions in the hospital setting have been caused by S aureus. 20 The proportion of hospital-onset S aureus infections that were methicillin-resistant reached 64.4% in US intensive care units in 2003. 21 In the hospital, MRSA infec tions are associated with greater lengths of stay, higher mortality, 22 and in creased costs. 23, 24 Although more re cently there has been increased surveil lance activity for invasive MRSA infections in the community, surveil lance for MRSA bloodstream infec tions in the United States traditionally has been limited to hospital-onset (ie, nosocomial) disease. 20, 21 As the epidemiology of MRSA dis ease changes, including both commu nity-and health care-associated dis ease, accurate information on the scope and magnitude of the burden of MRSA disease in the US population is needed to set priorities for prevention and con trol. In this report we describe the in cidence and distribution of invasive MRSA disease in 9 US communities and use these results to estimate the bur den of invasive MRSA infections in the United States.
METHODS

Surveillance Methodology and Definitions
The Active Bacterial Core surveillance system (ABCs) is an ongoing, popula tion-based, active laboratory surveil lance system and is a component of the Emerging Infections Program (EIP) of the US Centers for Disease Control and Prevention (CDC). From July 2004 through December 2005, 9 EIP sites con ducted surveillance for invasive MRSA infections. A site number was assigned in descending order of population size: site 1, the state of Connecticut (esti mated population, 3.5 million); site 2, the Atlanta, Georgia, metropolitan area (8 counties; estimated population, 3.5 million); site 3, the San Francisco, Cali fornia, Bay Area (3 counties; estimated population, 3.2 million); site 4, the Den ver, Colorado, metropolitan area (5 counties; estimated population, 2.3 mil lion); site 5, the Portland, Oregon, met ropolitan area (3 counties; estimated population, 1.5 million); site 6, Mon roe County, New York (estimated popu lation, 733 000); site 7, Baltimore City, Maryland (estimated population, 636 000); site 8, Davidson County, Ten nessee (estimated population, 575 000); and site 9, Ramsey County (St Paul area), Minnesota (estimated population, 495 000). The total population under surveillance in 2005 was an estimated 16.5 million, or approximately 5.6% of the US population. Surveillance sites were similar to the US population in the distribution by male sex (49.2% and 49.3%, respectively); however, surveil lance sites had a lower frequency of whites (72.7% and 81.0%, respec tively) and of persons 65 years and older (10.8% and 12.4%, respectively).
ABCs case finding was both active and laboratory-based. Clinical micro biology laboratories in acute care hos pitals and all reference laboratories pro cessing sterile site specimens for residents of the surveillance area were contacted regularly for case identifica tion. In hospitals without computer ized microbiology data, surveillance personnel telephoned designated mi crobiology laboratory contacts regu larly to identify new cases and request isolate submission. Where microbiol ogy data were computerized, elec tronic line listings of all MRSA iso lated from normally sterile sites were received on a monthly basis by surveil lance staff, which investigated each po tential case to confirm residency sta tus, presence of infection, demographic characteristics, and underlying ill ness. The burden of disease can be es timated by this surveillance method using census data and the surveillance site-specific incidence rates and age-, race-, and sex-adjusted incidence rates pooled across all surveillance sites. This infrastructure is the same as that used for estimated incidence and disease bur den for bacterial meningitis 25 and in vasive infections with Streptococcus 26, 27 pneumoniae.
Case reporting and isolate collec tion were determined to be surveil lance activities at the CDC; in addi tion, each of the 9 participating surveillance sites evaluated the proto col and either deemed it a surveillance activity (eg, that involving a report able disease) or obtained institutional review board approval with a waiver of informed consent.
A case of invasive MRSA infection was defined by the isolation of MRSA from a normally sterile body site in a resident of the surveillance area, in cluding residents institutionalized in long-term care facilities, prisons, etc. Normally sterile sites included blood, cerebrospinal fluid, pleural fluid, peri cardial fluid, peritoneal fluid, joint/ synovial fluid, bone, internal body site (lymph node, brain, heart, liver, spleen, vitreous fluid, kidney, pancreas, or ovary), or other normally sterile sites. Cultures designated as "fluid" were in vestigated as potentially sterile cul ture sites; cultures designated as "tis sue" with no specification of original source were not investigated.
Personnel in each EIP site abstracted data from medical records from hospital and clinic visits using a standard case report form. Information on the following health care risk factors for MRSA was collected: culture obtained more than 48 hours after admission; presence of an invasive device (eg, vascular catheter, gastric feeding tube) at time of admission or evaluation; and a history of MRSA infection or colonization, surgery, hospi talization, dialysis, or residence in a longterm care facility in the 12 months preceding the culture. Cases could have more than 1 health care risk factor. For this analysis, we used health care risk fac tor information to classify cases into mu tually exclusive groups (those with health care-associated and communityassociated infections) justified previ ously 28 and consistent with other stud ies (TABLE 1). 2 9 , 3 0 Health careassociated infections, in turn, were classified as either community-onset (cases with a health care risk factor but with a culture obtained �48 hours af ter hospital admission) and hospitalonset (cases with culture obtained �48 hours after admission, regardless of whether they also had other health care risk factors). Community-associated cases were those without documented health care risk factors.
Surveillance personnel also col lected demographic (including race), clinical, and outcome (hospital death or discharge) information on each case from the initial hospitalization. Mortal ity was collected from the patient rec ord and represented crude, in-hospital deaths only. Race was collected from in formation available in the medical rec ord. Cases were considered to have a di agnosis of bacteremia, pneumonia, cellulitis, osteomyelitis, endocarditis, septic shock, or other infection, if there was documentation of such a diagnosis in the medical record, regardless of the source of the isolate. Cases could have more than 1 clinical diagnosis. Bactere mias included those classified as pri mary, secondary, and not specified. Use of up to 4 antimicrobial agents was re corded, but all such agents reflected only initial empirical therapy and did not in 
Isolate Collection and Testing
Laboratories identified by the EIP site were asked to submit isolates from in vasive MRSA infections. Of 123 labo ratories serving residents of the sur veillance areas, 48 (39%) contributed isolates. All isolates were sent to the CDC for identification, selected test ing, and storage. In situations in which more than 1 isolate was available from a single case, the protocol selected 1 iso late, preferably from a nonblood ster ile site. Isolates were prioritized for test ing as follows: within each geographic site, all nonblood isolates and the sub sequent submitted blood isolate were selected; then, among blood isolates, those from cases with a diagnosis other than uncomplicated bacteremia were selected. Testing included confirma tion of S aureus identification using catalase and Staphaurex (Remel Eu rope Ltd, Dartford, United Kingdom) agglutination tests and tube coagulase if necessary, as well as description of morphology on nonselective blood agar, confirmation of oxacillin resistance by the broth microdilution method, 18 and pulsed-field gel electrophoresis (PFGE) using the restriction endonuclease SmaI. PFGE patterns were analyzed using BioNumerics version 4.01 (Ap plied Maths, Austin, Texas) and grouped into pulsed-field types using Dice coefficients and 80% relatedness, as previously described. 18 PFGE test ing was conducted at the CDC and at the reference centers in Colorado, Con necticut, Georgia, Minnesota, and Or egon. All PFGE patterns were entered into a single database for analysis.
Statistical Analysis
We selected cases reported from Because the surveillance sites var ied in the distribution by age and race, for national estimates of burden of dis ease we multiplied the aggregate age-, race-, and sex-specific rates of disease in the surveillance areas by the age, race, and sex distribution of the US popula tion for 2005. Because 1 site (site 7, Bal timore City) reported an excessively high incidence of infection, we calcu lated interval estimates for the age-, race-, and sex-adjusted incidence rates and estimated burden as well. This was performed by creating a lower bound by pooling data from the 3 EIP sites a Interval estimates for the overall incidence by race were calculated for the lower bound by pooling data from the 3 surveillance sites reporting the lowest incidence rates; for the upper bound, by pooling data from the 3 sites report ing the highest rates, excluding data from site 7 (Baltimore City), which reported excessively high rates. These racespecific interval estimates are adjusted by age and sex.
with lowest overall incidence (sites 4, 5, and 9) and an upper bound by pool ing data from the 3 EIP sites with high est overall incidence (sites 2, 6, and 8), excluding site 7. Because data from site 7 were excluded from the interval es timates, there are occasions when the intervals do not include the overall rate. Confidence intervals are based on the properties of a sampling distribution and cannot be calculated with our data because our surveillance areas cap tured all cases, not a sample. We tested differences in proportions of descrip tive characteristics using � 2 . Analyses were performed using SAS version 9.1.3 (SAS Institute Inc, Cary, North Caro lina).
RESULTS
Incidence of Invasive MRSA
There were 8987 observed cases of in vasive MRSA reported from July 2004 through December 2005. Most were health care-associated, with 5250 (58.4%) community-onset infections, 2389 (26.6%) hospital-onset infec tions, 1234 (13.7%) communityassociated infections, and 114 (1.3%) that could not be classified.
Unadjusted incidence rates of all types of invasive MRSA ranged between ap proximately 20 to 50 per 100 000 in most ABCs sites but were noticeably higher in 1 site (site 7, Baltimore City) (TABLE 2). The rate of invasive communityassociated MRSA was less than 3 per 100 000 in 4 sites and approximately 5 per 100 000 in 3 sites. Incidence rates were consistently higher among blacks compared with whites in the various age groups (TABLE 3) . Adjusting for age, race, and sex, the standardized incidence rate of invasive MRSA for calendar year 2005 was 31.8 per 100 000 persons (TABLE 4). The overall interval estimate after exclu sion of the outlier site (site 7) was 24.4 to 35.2 per 100 000.
The rate of health care-associated, community-onset infections (17.6 per 100 000; interval estimate, 14.7-18.2) was greater than either health careassociated, hospital-onset infections (8.9 per 100 000; interval estimate, 6.1 11.8) or community-associated infec tions (4.6 per 100 000; interval esti mate, 3.6-4.4). Standardized incidence rates overall were highest among per sons 65 years and older (127.7 per 100 000; interval estimate, 92.6-156.9), blacks (66.5 per 100 000; interval esti mate, 43.5-63.1), and males (37.5 per 100 000; interval estimate, 26.8-39.5) ( Table 4) . Rates were lowest among per sons aged 5 to 17 years (1.4 per 100 000; interval estimate, 0.8-1.7).
The standardized mortality rate was 6.3 per 100 000 (interval estimate, 3.3-7.5) overall, and was higher among persons 65 years and older (35.3 per 100 000; interval estimate, 18.4 44.7), blacks (10.0 per 100 000; inter val estimate, 5.7-9.9), and males (7.4 per 100 000; interval estimate, 3.7 8.9) ( Table 4) . Among persons with MRSA, mortality for health careassociated, community-onset infec tions was higher (3.2 per 100 000; in terval estimate, 1.7-3.7) than for health care-associated, hospital-onset infec tions (2.5 per 100 000; interval esti mate, 1.2-3.1) or for communityassociated infections (0.5 per 100 000; interval estimate, 0.3-0.6).
There empirical therapy (75%), followed by semisynthetic penicillins (28%) and fluoroquinolones (26%). Similar pro portions of cases were prescribed monotherapy (31.3%), therapy with 2 anti microbials (37.9%), or therapy with more than 2 antimicrobials (30.9%).
Pulsed-Field Typing
PFGE results were available for 864 of the 1201 (71.9%) isolates received from 8 of the 9 ABCs sites (isolates were not available from site 7); these results rep resent 11.3% of the 7648 cases re ported from these 8 sites (TABLE 6) . Of these results, 81.6% were from blood cultures, 4.7% from bone, 4.8% from synovial fluid, 1.9% from pleural fluid, 1.5% from peritoneal fluid, and the re maining 5.5% from other normally ster ile sites; this culture site distribution is similar to the distribution of culture sites reported among all 8987 cases. Iso lates tested were associated with all of the major clinical conditions previ ously described, including uncompli cated bacteremia (69.8%), pneumonia (19.3%), cellulitis (11.3%), osteomy elitis (10.4%), endocarditis (8.5%), and septic shock (5.0%). USA300 was the strain type identi fied for 100 of 150 (66.6%) isolates from community-associated cases and also was found among 108 of 485 (22.2%) isolates from health care-associated, community-onset cases and among 34 of 216 (15.7%) health care-associated, hospitalonset cases (TABLE 7) . Also, 35 of 1 5 0 ( 2 3 . 0 % ) i s o l a t e s f r o m community-associated cases were USA100. In contrast, other strains of c o m m u n i t y o r i g i n ( U S A 4 0 0 , USA1000) were rare, accounting for only 3 of 150 (2.0%) isolates from community-associated cases, perhaps reflecting that these isolates all come from normally sterile sites and not skin abscesses, where these strain types have often been reported. USA100 and USA300 were the pre dominant pulsed-field types in each surveillance site, with the exception of site 1 (state of Connecticut) ( Table 6 ).
COMMENT
These data represent the first US nationwide estimates of the burden of invasive MRSA disease using populationbased, active case finding. Based on 8987 observed cases of MRSA and 1598 in-hospital deaths among patients with MRSA, we estimate that 94 360 inva sive MRSA infections occurred in the United States in 2005; these infections were associated with death in 18 650 cases. The standardized incidence rate of invasive MRSA for calendar year 2005 was 31.8 per 100 000 persons. The in cidence of other important invasive pathogens in 2005, such as invasive in fections with S pneumoniae or Hae mophilus influenzae, ranged from 14.0 per 100 000 to less than 1 per 100 000, largely due to the availability and suc cess of vaccination. [31] [32] [33] The estimated 94 360 infections is larger than the estimate from a recent study using hospital discharge-coded data; in 2000, the CDC estimated that there were 31 440 hospitalizations for MRSA bacteremias (ie, septicemia) in the United States. 34 Some of the dis crepancy may relate to a more inclu sive definition of invasive disease in our study and to the limitations inherent in discharge coded data. Of the esti mated 94 360 infections from this study, 75.2% were bacteremias, and 26.6% were of hospital onset; thus, our esti mates would yield approximately 18 900 MRSA, hospital-onset bactere mias. In 2002, the CDC estimated that there were 248 678 hospital-acquired bacteremias in the United States, 35 of which approximately 20 390 (8.2%) could be expected to be MRSA 20 -a re sult consistent with our findings.
Regarding community-associated MRSA, noninvasive infections with MRSA greatly outnumber invasive MRSA infections. In fact, when 3 of the ABCs sites began surveillance in 2000 for all MRSA infections, only 7% rep resented invasive disease. However, findings described here further docu ment that invasive MRSA disease does occur in persons without established health care risk factors, 28 is associated with strains of both community and 
4 (2) 6 (1) 3 (2) 1 (8) 14 (2) Not typeable b 2 (1) 12 (2) a Epidemiologic classification of disease consisted of health care-associated (either hospital-onset cases with a culture collected �48 h after hospital admission or community-onset cases with health care risk factors but a culture col lected �48 h after hospital admission) and community-associated cases (those with no health care risk factors). b SmaI pulsed-field gel electrophoresis typing was successful in giving these isolates a pattern number, but numbers were outside of the 80% similarity range.
health care origin, 36 and is associated with significant mortality. Molecular analysis of isolates in our study provides evidence supporting other studies 36 showing that strains of community ori gin do now cause some hospital-onset disease but also that, overall, most in vasive MRSA disease is still caused by MRSA strains of health care origin.
Compared with rates of invasive MRSA infections in 2 of our sites from 2001-2002, the incidence of invasive MRSA has increased in 2005 from 19.3 per 100 000 to 33.0 per 100 000 in At lanta and from 40.4 per 100 000 to 116.7 per 100 000 in Baltimore. 13 These increases were in both community-and health care-associated disease. How ever, in the state of Connecticut, the rate of community-onset MRSA bactere mias has been relatively stable at 2.5 per 100 000 in 1998 29 and 2.8 per 100 000 in 2005.
We describe striking differences in rates of invasive MRSA infections by race among all age groups. Connecti cut documented a disparity for com munity-onset S aureus bacteremias in 1998. 29 More recently, surveillance in Atlanta reported a significantly higher rate of community-associated MRSA among blacks compared with whites 13 ; however, little progress has been made in understanding why. It is likely that the prevalence of underlying condi tions, 37 at least some of which vary by race, 38 may play a role. The incidence of invasive pneumococcal disease var ies widely by underlying chronic ill ness, but racial disparities persist for all conditions evaluated. 39 MRSA preva lence has been linked to socioeco nomic status, 40 and this might con found the association between race and incidence of MRSA. Future analyses should focus on understanding rea sons for differences in MRSA inci dence rates.
The geographic variability in MRSA rates has been documented in other studies. 3, 13 In this study we found that areas with lower incidence rates of in vasive MRSA overall did not always have lower rates of communityassociated MRSA. For example, site 6 (Monroe County, New York) had a rela tively high rate of invasive MRSA over all (41.9 per 100 000) but a low rate of community-associated MRSA (2.7 per 100 000); site 5 (the Portland, Or egon, metro area) had a relatively low rate of invasive MRSA overall (19.8 per 100 000) but a high rate of communityassociated MRSA (4.7 per 100 000). In addition to factors already mentioned such as socioeconomic status and un derlying conditions, MRSA rates may be higher in urban areas. 29 As with dif ferences in the incidence of invasive MRSA by race, geographic differences are probably multifactorial and com plex. Improved understanding can help design and focus prevention messages as well as increase the timeliness of di agnosis and clinical management of in vasive infections.
The majority of invasive MRSA cases occurred outside of the hospital (58%) but among persons with established risk factors for MRSA, such as a history of hospitalization in the past year. This ob servation was also made recently in a study from a single facility. 30 Patients with health care risk factors and com munity-onset disease likely acquired the pathogen from their health care con tacts, such as those from a recent hos pitalization or nursing home resi dence. Molecular analysis suggests that most of these infections were caused by MRSA strains of health care origin. If, in fact, these infections represent ac quisition during transitions of care from acute care, 41 it follows that strategies to prevent and control MRSA among in patients, 42, 43 if properly applied, may have an impact on these infections as well as on the traditional hospitalonset infections. Since interventions for MRSA prevention are inconsistently implemented in US hospitals, 44 corre lating the impact on either inpatient or outpatient disease will be challenging. Interventions used in the community to control outbreaks consist of improv ing hygiene and infection control along with enhanced surveillance, diagno sis, and appropriate treatment of infections [45] [46] [47] ; however, studies of the effectiveness of community-based pre vention and control interventions are lacking.
Our estimates have certain limita tions. First, we may have underesti mated the incidence of invasive MRSA disease if persons in the surveillance areas sought health care from facili ties using laboratories outside the sur veillance area. However, any underes timate is probably minor in light of the estimates derived from discharge data on MRSA hospitalizations. 34 Second, we may have overestimated the incidence of community-associ ated MRSA if health care risk factors were not well documented in medical records. During surveillance con ducted in 2000-2001, patient inter views were used to elicit undocu mented health care risk factors; however, the effect on reclassification was small. 13 Third, our surveillance sites were largely urban areas; thus, we might be overestimating the incidence of inva sive MRSA. 29 Although our surveil lance areas comprise a diverse set of regions and are likely representative of the United States, it is not known whether the incidence rates in the observed populations are actually rep resentative of the distribution of inci dence rates in other US cities. Since the methodology of population-based sur veillance produces a single point esti mate without confidence intervals (ie, all cases are identified), we calculated interval estimates excluding site 7 (Bal timore City) to allow the reader to inter pret a range of estimates reflecting dif ferent metropolitan areas. Regarding the high observed incidence rates reported by site 7, we conducted an evaluation to determine whether these results were valid, including a review of casefinding methods, elimination of cases to include only those with zip codes rep resented in the denominator, contami nation in any laboratory, and other potential causes for increased rates; however, none were in error.
Fourth, our measures of deaths rep resented crude, in-hospital deaths, rather than attributable mortality. It is possible that MRSA infection did not cause or contribute to some deaths.
Fifth, the evaluation of isolates in this study was meant to describe strain di versity and to shed light on the poten tial crossover of strains from a commu nity origin into the hospital setting. The isolate collection was a convenience sample. Furthermore, we only had test results from isolates of 864 (11.3%) of the cases reported; extrapolation of the molecular characterization to the US population should be avoided.
In conclusion, invasive MRSA dis ease is a major public health problem and is primarily related to health care but no longer confined to acute care. Although in 2005 the majority of in vasive disease was related to health care, this may change.
